9 Meters Biopharma Inc
OTC:NMTRQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (0.2), the stock would be worth $0 (0% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | $0 |
0%
|
| 3-Year Average | 0.2 | $0 |
0%
|
| 5-Year Average | 0.2 | $0 |
-5%
|
| Industry Average | 12.1 | $0.04 |
+7 472%
|
| Country Average | 19.6 | $0.06 |
+12 185%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$-6.9m
|
/ |
Apr 2023
$-43.5m
|
= |
|
|
$-6.9m
|
/ |
Dec 2023
$-39.5m
|
= |
|
|
$-6.9m
|
/ |
Dec 2024
$-53.7m
|
= |
|
|
$-6.9m
|
/ |
Dec 2025
$-44.9m
|
= |
|
|
$-6.9m
|
/ |
Dec 2026
$-27.4m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
9 Meters Biopharma Inc
OTC:NMTRQ
|
144.6 USD | 0.2 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 30.6 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 22 | 26.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 23.6 | 30.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 16.2 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 12.2 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.7 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 10.3 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 8.9 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
9 Meters Biopharma Inc
Glance View
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.
